WO2002100348A3 - Human monoclonal antibodies to epidermal growth factor receptor (egfr) - Google Patents

Human monoclonal antibodies to epidermal growth factor receptor (egfr) Download PDF

Info

Publication number
WO2002100348A3
WO2002100348A3 PCT/US2002/018748 US0218748W WO02100348A3 WO 2002100348 A3 WO2002100348 A3 WO 2002100348A3 US 0218748 W US0218748 W US 0218748W WO 02100348 A3 WO02100348 A3 WO 02100348A3
Authority
WO
WIPO (PCT)
Prior art keywords
human
antibodies
monoclonal antibodies
egfr
human monoclonal
Prior art date
Application number
PCT/US2002/018748
Other languages
French (fr)
Other versions
WO2002100348A8 (en
WO2002100348A2 (en
Inventor
De Winkel Jan Van
Dijk Marcus A Van
Arnout F Gerritsen
Edward Halk
Original Assignee
Genmab As
Medarex Inc
De Winkel Jan Van
Dijk Marcus A Van
Arnout F Gerritsen
Edward Halk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to BRPI0210405 priority Critical patent/BRPI0210405B8/en
Priority to AU2002345673A priority patent/AU2002345673B2/en
Priority to MXPA03011365A priority patent/MXPA03011365A/en
Priority to HU0600225A priority patent/HUP0600225A3/en
Application filed by Genmab As, Medarex Inc, De Winkel Jan Van, Dijk Marcus A Van, Arnout F Gerritsen, Edward Halk filed Critical Genmab As
Priority to EP02744320.9A priority patent/EP1417232B1/en
Priority to NZ530212A priority patent/NZ530212A/en
Priority to IL15922502A priority patent/IL159225A0/en
Priority to KR1020037016294A priority patent/KR100945108B1/en
Priority to CA2450285A priority patent/CA2450285C/en
Priority to JP2003503174A priority patent/JP4298498B2/en
Publication of WO2002100348A2 publication Critical patent/WO2002100348A2/en
Publication of WO2002100348A3 publication Critical patent/WO2002100348A3/en
Publication of WO2002100348A8 publication Critical patent/WO2002100348A8/en
Priority to IL159225A priority patent/IL159225A/en
Priority to HK04107653.9A priority patent/HK1064685A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Abstract

Isolated human monoclonal antibodies which specifically bind to human EGFR, and related antibody-based compositions and molecules, are disclosed. The human antibodies can be produced by a transgenic mouse, capable of producing multiple isotypes of human nonoclonal antibodies by undergoing V-D-J recombination and isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, non-human transgenic animals and hybridomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.
PCT/US2002/018748 2001-06-13 2002-06-13 Human monoclonal antibodies to epidermal growth factor receptor (egfr) WO2002100348A2 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
NZ530212A NZ530212A (en) 2001-06-13 2002-06-13 An isolated human monoclonal antibody that binds to human epidermal growth factor receptor (EGFR)
MXPA03011365A MXPA03011365A (en) 2001-06-13 2002-06-13 Human monoclonal antibodies to epidermal growth factor receptor (egfr).
HU0600225A HUP0600225A3 (en) 2001-06-13 2002-06-13 Human monoclonal antibodies to epidermal growth factor receptor (egfr)
KR1020037016294A KR100945108B1 (en) 2001-06-13 2002-06-13 Human Monoclonal Antibodies to Epidermal Growth Factor Receptor EGFR
EP02744320.9A EP1417232B1 (en) 2001-06-13 2002-06-13 Human monoclonal antibodies to epidermal growth factor receptor (egfr)
AU2002345673A AU2002345673B2 (en) 2001-06-13 2002-06-13 Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
IL15922502A IL159225A0 (en) 2001-06-13 2002-06-13 Human monoclonal antibodies to epidermal growth factor receptor (egfr)
BRPI0210405 BRPI0210405B8 (en) 2001-06-13 2002-06-13 human monoclonal antibody, bispecific molecule, in vitro method to inhibit the growth of a cell expressing egfr, to induce cytolysis of a cell expressing egfr, and to detect the presence of egfr antigen or a cell expressing egfr in a sample, e, vector of expression
CA2450285A CA2450285C (en) 2001-06-13 2002-06-13 Human monoclonal antibodies to epidermal growth factor receptor (egfr)
JP2003503174A JP4298498B2 (en) 2001-06-13 2002-06-13 Human monoclonal antibody against epidermal growth factor receptor (EGFR)
IL159225A IL159225A (en) 2001-06-13 2003-12-07 Human monoclonal antibodies to epidermal growth factor receptor (egfr)
HK04107653.9A HK1064685A1 (en) 2001-06-13 2004-10-06 Human monoclonal antibodies to epidermal growth factor receptor (egfr) (egfr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29817201P 2001-06-13 2001-06-13
US60/298,172 2001-06-13

Publications (3)

Publication Number Publication Date
WO2002100348A2 WO2002100348A2 (en) 2002-12-19
WO2002100348A3 true WO2002100348A3 (en) 2003-02-27
WO2002100348A8 WO2002100348A8 (en) 2003-04-10

Family

ID=23149369

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/018748 WO2002100348A2 (en) 2001-06-13 2002-06-13 Human monoclonal antibodies to epidermal growth factor receptor (egfr)

Country Status (16)

Country Link
US (1) US7247301B2 (en)
EP (1) EP1417232B1 (en)
JP (2) JP4298498B2 (en)
KR (2) KR20090125840A (en)
CN (2) CN1966525A (en)
AU (1) AU2002345673B2 (en)
BR (1) BRPI0210405B8 (en)
CA (1) CA2450285C (en)
CZ (1) CZ200438A3 (en)
HK (1) HK1064685A1 (en)
HU (1) HUP0600225A3 (en)
IL (2) IL159225A0 (en)
MX (1) MXPA03011365A (en)
NZ (1) NZ530212A (en)
RU (1) RU2335507C2 (en)
WO (1) WO2002100348A2 (en)

Families Citing this family (254)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7060808B1 (en) * 1995-06-07 2006-06-13 Imclone Systems Incorporated Humanized anti-EGF receptor monoclonal antibody
US20030224001A1 (en) * 1998-03-19 2003-12-04 Goldstein Neil I. Antibody and antibody fragments for inhibiting the growth of tumors
ZA200007412B (en) * 1998-05-15 2002-03-12 Imclone Systems Inc Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases.
RU2294761C2 (en) * 1999-05-14 2007-03-10 Имклон Систимс Инкопэритид Method for treating resistant human tumors with epidermis growth factor receptors antagonists
AU9500201A (en) * 2000-08-09 2002-02-18 Imclone Systems Inc Treatment of hyperproliferative diseases with epidermal growth factor receptor antagonists
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20080008704A1 (en) * 2001-03-16 2008-01-10 Mark Rubin Methods of treating colorectal cancer with anti-epidermal growth factor antibodies
DE60234094D1 (en) 2001-05-11 2009-12-03 Ludwig Inst For Cancer Res Ltd SPECIFIC TIE PROTEINS AND ITS USE
US20100056762A1 (en) 2001-05-11 2010-03-04 Old Lloyd J Specific binding proteins and uses thereof
US7595378B2 (en) 2001-06-13 2009-09-29 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
US20050271663A1 (en) * 2001-06-28 2005-12-08 Domantis Limited Compositions and methods for treating inflammatory disorders
WO2004058821A2 (en) * 2002-12-27 2004-07-15 Domantis Limited Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand
WO2003002609A2 (en) * 2001-06-28 2003-01-09 Domantis Limited Dual-specific ligand and its use
AU2003222568B2 (en) 2002-01-11 2009-05-07 Bioasis Technologies, Inc. Use of P97 as an enzyme delivery system for the delivery of therapeutic lysosomal enzymes
US20090042291A1 (en) * 2002-03-01 2009-02-12 Xencor, Inc. Optimized Fc variants
US7662925B2 (en) * 2002-03-01 2010-02-16 Xencor, Inc. Optimized Fc variants and methods for their generation
CN1678634A (en) * 2002-06-28 2005-10-05 多曼蒂斯有限公司 Immunoglobulin single variable antigen combination area and its opposite constituent
US9321832B2 (en) * 2002-06-28 2016-04-26 Domantis Limited Ligand
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
PT2314629E (en) * 2002-07-18 2014-01-22 Merus B V Recombinant production of mixtures of antibodies
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
DE10303974A1 (en) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid β (1-42) oligomers, process for their preparation and their use
US8388955B2 (en) * 2003-03-03 2013-03-05 Xencor, Inc. Fc variants
US20090010920A1 (en) * 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
CA2450289A1 (en) * 2003-03-20 2005-05-19 Imclone Systems Incorporated Method of producing an antibody to epidermal growth factor receptor
EP1622941A2 (en) * 2003-03-20 2006-02-08 ImClone Systems Incorporated Method of producing an antibody to epidermal growth factor receptor
ES2408582T3 (en) 2003-05-30 2013-06-21 Merus B.V. Fab library for the preparation of a mixture of antibodies
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
US8101720B2 (en) 2004-10-21 2012-01-24 Xencor, Inc. Immunoglobulin insertions, deletions and substitutions
US9714282B2 (en) 2003-09-26 2017-07-25 Xencor, Inc. Optimized Fc variants and methods for their generation
GB0324368D0 (en) * 2003-10-17 2003-11-19 Univ Cambridge Tech Polypeptides including modified constant regions
EP1737971B1 (en) 2004-01-20 2017-08-16 Merus N.V. Mixtures of binding proteins
US7767792B2 (en) * 2004-02-20 2010-08-03 Ludwig Institute For Cancer Research Ltd. Antibodies to EGF receptor epitope peptides
AU2005224267B2 (en) * 2004-03-19 2011-07-21 Imclone Llc Human anti-epidermal growth factor receptor antibody
JP2008512352A (en) * 2004-07-17 2008-04-24 イムクローン システムズ インコーポレイティド Novel tetravalent bispecific antibody
ES2635497T3 (en) 2004-07-22 2017-10-04 Erasmus University Medical Center Rotterdam Binding molecules
EP2314618A3 (en) 2004-11-12 2011-10-19 Xencor Inc. Fc variants with altered binding to FcRn
US8367805B2 (en) * 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
US8546543B2 (en) 2004-11-12 2013-10-01 Xencor, Inc. Fc variants that extend antibody half-life
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
PL1871805T3 (en) * 2005-02-07 2020-03-31 Roche Glycart Ag Antigen binding molecules that bind egfr, vectors encoding same, and uses thereof
CN100362018C (en) * 2005-03-02 2008-01-16 上海张江生物技术有限公司 Recombinant monoclonal antibody against EGFR
US7829673B2 (en) 2005-03-23 2010-11-09 Genmab A/S Antibodies against CD38 for treatment of multiple myeloma
US20060257317A1 (en) * 2005-05-04 2006-11-16 Duke University Combination therapy in the treatment of cancer
CA2605781A1 (en) * 2005-05-09 2007-04-12 Glycart Biotechnology Ag Antigen binding molecules having modified fc regions and altered binding to fc receptors
EA200800094A1 (en) * 2005-06-20 2008-06-30 Медарекс, Инк. ANTIBODIES CD19 AND THEIR USE
US7449442B2 (en) * 2005-07-12 2008-11-11 Children's Medical Center Corporation EGFR inhibitors promote axon regeneration
US9580506B2 (en) 2005-07-21 2017-02-28 Genmab A/S Potency assays for antibody drug substance binding to an Fc receptor
SI2298815T1 (en) 2005-07-25 2015-08-31 Emergent Product Development Seattle, Llc B-cell reduction using CD37-specific and CD20-specific binding molecules
US7612181B2 (en) * 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
US20090215992A1 (en) * 2005-08-19 2009-08-27 Chengbin Wu Dual variable domain immunoglobulin and uses thereof
JP5376948B2 (en) * 2005-09-13 2013-12-25 ナショナル リサーチ カウンシル オブ カナダ Methods and compositions for modulating tumor cell activity
CA2624189A1 (en) 2005-10-03 2007-04-12 Xencor, Inc. Fc variants with optimized fc receptor binding properties
AU2006319358B2 (en) 2005-11-30 2012-01-19 AbbVie Deutschland GmbH & Co. KG Anti-Abeta globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies
RS53270B2 (en) 2005-11-30 2018-05-31 Abbvie Deutschland Monoclonal antibodies against amyloid beta protein and uses thereof
AU2006321364B2 (en) * 2005-12-01 2011-11-10 Domantis Limited Noncompetitive domain antibody formats that bind Interleukin 1 Receptor type 1
SG177194A1 (en) 2005-12-08 2012-01-30 Medarex Inc Human monoclonal antibodies to protein tyrosine kinase 7 (ptk7) and methods for using anti-ptk7 antibodies
CN101058609B (en) * 2006-05-26 2011-04-13 神州细胞工程有限公司 Human antibody and expression thereof
CA3149553C (en) 2006-06-12 2023-11-21 Aptevo Research And Development Llc Single-chain multivalent binding proteins with effector function
CA2656620C (en) 2006-07-04 2018-03-13 Genmab A/S Cd20 binding molecules for the treatment of copd
AR062223A1 (en) * 2006-08-09 2008-10-22 Glycart Biotechnology Ag MOLECULES OF ADHESION TO THE ANTIGEN THAT ADHER TO EGFR, VECTORS THAT CODE THEM, AND THEIR USES OF THESE
HUE044136T2 (en) 2006-09-26 2019-09-30 Genmab As Anti-cd38 plus corticosteroids plus a non-corticosteroid chemotherapeutic for treating tumors
WO2008045373A2 (en) * 2006-10-06 2008-04-17 Amgen Inc. Stable antibody formulations
ES2925992T3 (en) * 2006-10-20 2022-10-20 Amgen Inc Stable formulations of polypeptides
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
CN104013956B (en) 2007-01-25 2018-12-18 达娜-法勃肿瘤研究所公司 Purposes of the anti-egfr antibodies in the mutant mediated disease for the treatment of EGFR
EP2486928A1 (en) 2007-02-27 2012-08-15 Abbott GmbH & Co. KG Method for the treatment of amyloidoses
KR101676622B1 (en) * 2007-03-01 2016-11-17 심포젠 에이/에스 Recombinant anti-epidermal growth factor receptor antibody compositions
WO2008115404A1 (en) 2007-03-15 2008-09-25 Ludwing Institute For Cancer Research Treatment method using egfr antibodies and src inhibitors and related formulations
EP2139924B1 (en) 2007-03-29 2016-07-06 Genmab A/S Bispecific antibodies and methods for production thereof
BRPI0809594A2 (en) * 2007-04-03 2019-08-27 Micromet Ag polypeptide, nucleic acid sequence, vector, host, process for producing a polypeptide, pharmaceutical composition, use of a polypeptide, method for preventing, treating or ameliorating a disease in an individual in need thereof, kit, method for the identification of a polypeptide (s)
MX2009010611A (en) * 2007-04-03 2010-03-26 Micromet Ag Cross-species-specific bispecific binders.
AU2008255352B2 (en) 2007-05-31 2014-05-22 Genmab A/S Stable IgG4 antibodies
CA2689695A1 (en) 2007-05-31 2008-12-04 Genmab A/S Transgenic animals producing monovalent human antibodies and antibodies obtainable from these animals
EA200901301A1 (en) * 2007-06-06 2010-06-30 Домантис Лимитед POLYPEPTIDES, VARIABLE DOMAINS OF ANTIBODIES AND ANTAGONISTS
US20100322939A1 (en) * 2007-06-21 2010-12-23 Genmab A/S Novel methods for treating egfr-associated tumors
MX2010001757A (en) 2007-08-14 2010-09-14 Ludwig Inst Cancer Res Monoclonal antibody 175 targeting the egf receptor and derivatives and uses thereof.
WO2009030239A1 (en) * 2007-09-06 2009-03-12 Genmab A/S Novel methods and antibodies for treating cancer
ES2742268T3 (en) 2007-12-26 2020-02-13 Xencor Inc Fc variants with altered FcRn binding
JP6014706B2 (en) * 2008-02-14 2016-10-25 株式会社イーベック Monoclonal antibody binding to hGM-CSF and pharmaceutical composition comprising said antibody
EP2274437B1 (en) 2008-04-10 2015-12-23 Cell Signaling Technology, Inc. Compositions and methods for detecting egfr mutations in cancer
MX340204B (en) 2008-04-11 2016-06-30 Emergent Product Dev Seattle Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof.
US20100260668A1 (en) * 2008-04-29 2010-10-14 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
EP2282769A4 (en) 2008-04-29 2012-04-25 Abbott Lab Dual variable domain immunoglobulins and uses thereof
RU2010153580A (en) 2008-06-03 2012-07-20 Эбботт Лэборетриз (Us) IMMUNOGLOBULINS WITH TWO VARIABLE DOMAINS AND THEIR APPLICATION
CA2725666A1 (en) 2008-06-03 2009-12-10 Abbott Laboratories Dual variable domain immunoglobulins and uses thereof
CN101602808B (en) * 2008-06-12 2012-06-20 上海市肿瘤研究所 Specific binding protein and application thereof
JP5674654B2 (en) 2008-07-08 2015-02-25 アッヴィ・インコーポレイテッド Prostaglandin E2 double variable domain immunoglobulin and use thereof
AU2013202400B2 (en) * 2008-07-16 2014-10-09 Institute For Research In Biomedicine Human cytomegalovirus neutralizing antibodies and use thereof
MX2011001927A (en) 2008-08-29 2011-04-21 Symphogen As Recombinant anti-epidermal growth factor receptor antibody compositions.
LT2842573T (en) * 2008-11-07 2017-12-11 Galaxy Biotech, Llc Monoclonal antibodies to Fibroblast Growth Factor receptor 2
MX2011005953A (en) * 2008-12-04 2011-08-17 Abbott Lab Dual variable domain immunoglobulins and uses thereof.
US8835610B2 (en) 2009-03-05 2014-09-16 Abbvie Inc. IL-17 binding proteins
GB0905023D0 (en) 2009-03-24 2009-05-06 Univ Erasmus Medical Ct Binding molecules
TW201109438A (en) * 2009-07-29 2011-03-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
TW201119673A (en) 2009-09-01 2011-06-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
AR078161A1 (en) 2009-09-11 2011-10-19 Hoffmann La Roche VERY CONCENTRATED PHARMACEUTICAL FORMULATIONS OF AN ANTIBODY ANTI CD20. USE OF THE FORMULATION. TREATMENT METHOD
KR101108642B1 (en) * 2009-09-29 2012-02-09 주식회사 녹십자 Antibodies specifically binding to the epidermal growth factor receptor
TW201119676A (en) 2009-10-15 2011-06-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
UY32979A (en) * 2009-10-28 2011-02-28 Abbott Lab IMMUNOGLOBULINS WITH DUAL VARIABLE DOMAIN AND USES OF THE SAME
CN101875695B (en) * 2009-11-11 2012-07-04 中国人民解放军军事医学科学院生物工程研究所 Antibody, and coding gene and application thereof
CN101875696B (en) * 2009-11-11 2012-02-08 中国人民解放军军事医学科学院生物工程研究所 Antibody, and preparation method and application thereof
AU2010324506B2 (en) 2009-11-24 2015-02-26 Alethia Biotherapeutics Inc. Anti-clusterin antibodies and antigen binding fragments and their use to reduce tumor volume
US20110189178A1 (en) * 2010-02-04 2011-08-04 Xencor, Inc. Immunoprotection of Therapeutic Moieties Using Enhanced Fc Regions
MX336196B (en) 2010-04-15 2016-01-11 Abbvie Inc Amyloid-beta binding proteins.
MX353144B (en) 2010-04-20 2017-12-20 Genmab As Heterodimeric antibody fc-containing proteins and methods for production thereof.
KR20180053775A (en) † 2010-04-23 2018-05-23 제넨테크, 인크. Production of heteromultimeric proteins
HUE033063T2 (en) 2010-05-14 2017-11-28 Abbvie Inc Il-1 binding proteins
WO2011162904A2 (en) * 2010-05-24 2011-12-29 Marek Malecki Multidomain biotags for cancer detection, diagnosis and therapy and methods of their use priority statement
CA3051311A1 (en) 2010-05-27 2011-12-01 Genmab A/S Monoclonal antibodies against her2
WO2011154453A1 (en) 2010-06-09 2011-12-15 Genmab A/S Antibodies against human cd38
WO2011156617A2 (en) 2010-06-09 2011-12-15 Aveo Pharmaceuticals, Inc. Anti-egfr antibodies
JP5953303B2 (en) 2010-07-29 2016-07-20 ゼンコア インコーポレイテッド Antibodies with modified isoelectric points
CA2807014A1 (en) 2010-08-03 2012-02-09 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
WO2012024187A1 (en) 2010-08-14 2012-02-23 Abbott Laboratories Amyloid-beta binding proteins
CA2809433A1 (en) 2010-08-26 2012-03-01 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
KR101273918B1 (en) * 2010-09-17 2013-06-13 강원대학교산학협력단 A human anti-epidermal growth factor receptor Fab antibody and a pharmaceutical composition for treating tumor comprising the same
WO2012047225A2 (en) * 2010-10-08 2012-04-12 The General Hospital Corporation Methods of treating liver fibrosis and pre-cirrhosis with epidermal growth factor receptor inhibitors
BR112013010544A2 (en) 2010-10-29 2016-08-02 Immunogen Inc egfr and immunoconjugate binding molecules thereof
BR112013010569A2 (en) * 2010-10-29 2017-07-04 Immunogen Inc non-antagonistic and immunoconjugated egfr binding molecules thereof
RU2627171C2 (en) 2010-12-21 2017-08-03 Эббви Инк. Il-1 alpha and beta bispecific immunoglobulins with double variable domains and their application
KR102001686B1 (en) * 2011-04-07 2019-07-18 암젠 인크 Novel egfr binding proteins
CN102262155B (en) * 2011-04-12 2013-10-09 百泰生物药业有限公司 Method for measuring biological activity of recombined human epidermal growth factor and application of method
WO2012143524A2 (en) 2011-04-20 2012-10-26 Genmab A/S Bispecific antibodies against her2 and cd3
JP6177231B2 (en) 2011-04-20 2017-08-09 ゲンマブ エー／エス Bispecific antibody against HER2
US20130122024A1 (en) 2011-04-21 2013-05-16 Bayer Intellectual Property Gmbh New binder-drug conjugates (adcs) and use thereof
PT2717917T (en) 2011-07-05 2016-07-27 Bioasis Technologies Inc P97-antibody conjugates
UA117901C2 (en) 2011-07-06 2018-10-25 Ґенмаб Б.В. Antibody variants and uses thereof
NO2739649T3 (en) 2011-08-05 2018-02-24
US9273143B2 (en) 2011-09-30 2016-03-01 Regeneron Pharmaceuticals, Inc. Methods and compositions comprising a combination of an anti-ErbB3 antibody and an anti-EGFR antibody
EP2760893B1 (en) 2011-09-30 2018-09-12 Regeneron Pharmaceuticals, Inc. Anti-erbb3 antibodies and uses thereof
US10851178B2 (en) 2011-10-10 2020-12-01 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
EP2771364B1 (en) 2011-10-27 2019-05-22 Genmab A/S Production of heterodimeric proteins
US9637543B2 (en) 2011-11-09 2017-05-02 The Uab Research Foundation HER3 antibodies and uses thereof
CA2856411A1 (en) 2011-11-21 2013-05-30 Immunogen, Inc. Method of treatment of tumors that are resistant to egfr therapies by egfr antibody cytotoxic agent conjugate
PT2782598T (en) * 2011-11-23 2020-09-02 In3Bio Ltd Codan Services Ltd Recombinant proteins and their therapeutic uses
JP6180425B2 (en) 2011-11-23 2017-08-23 メディミューン，エルエルシー Binding molecules specific for HER3 and their use
CN103172741B (en) * 2011-12-20 2018-04-27 智翔（上海）医药科技有限公司 Full people source anti-egfr antibodies
BR112014015851A2 (en) 2011-12-30 2019-09-24 Abbvie Inc double specific binding proteins directed against il-13 and / or il-17
RU2650770C2 (en) * 2012-03-27 2018-04-17 Грин Кросс Корпорейшн Epitopes of epidermal growth factor receptor surface antigen and use thereof
HUE045944T2 (en) 2012-04-20 2020-02-28 Merus Nv Methods and means for the production of heterodimeric ig-like molecules
CN104918956A (en) * 2012-05-17 2015-09-16 索伦托治疗有限公司 Antigen binding proteins that bind EGFR
US9844582B2 (en) 2012-05-22 2017-12-19 Massachusetts Institute Of Technology Synergistic tumor treatment with extended-PK IL-2 and therapeutic agents
CA2875989A1 (en) 2012-06-08 2013-12-12 Sutro Biopharma, Inc. Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use
TWI641619B (en) 2012-06-25 2018-11-21 美商再生元醫藥公司 Anti-egfr antibodies and uses thereof
PT2869845T (en) * 2012-07-06 2019-12-09 Genmab Bv Dimeric protein with triple mutations
US9670276B2 (en) 2012-07-12 2017-06-06 Abbvie Inc. IL-1 binding proteins
AU2013296557B2 (en) 2012-07-31 2019-04-18 Bioasis Technologies Inc. Dephosphorylated lysosomal storage disease proteins and methods of use thereof
HUE045227T2 (en) 2012-08-31 2019-12-30 Sutro Biopharma Inc Modified amino acids comprising an azido group
EP2912062A1 (en) * 2012-10-24 2015-09-02 Yeda Research and Development Co. Ltd. Combinations of epidermal growth factor receptor targeting antibodies for treating cancer
SG11201503412RA (en) 2012-11-01 2015-05-28 Abbvie Inc Anti-vegf/dll4 dual variable domain immunoglobulins and uses thereof
CN102993305B (en) * 2012-11-16 2015-05-13 上海赛伦生物技术有限公司 Humanized anti-human epidemic growth factor receptor (EGFR) antibody as well as encoding gene and application thereof
US9695228B2 (en) * 2012-11-21 2017-07-04 Janssen Biotech, Inc. EGFR and c-Met fibronectin type III domain binding molecules
SI3447069T1 (en) * 2012-11-21 2021-02-26 Janssen Biotech, Inc. Bispecific egfr/c-met antibodies
CN113735967A (en) 2013-01-10 2021-12-03 根马布私人有限公司 Human IgG1 FC region variants and uses thereof
CA3211863A1 (en) 2013-01-14 2014-07-17 Xencor, Inc. Novel heterodimeric proteins
US10487155B2 (en) 2013-01-14 2019-11-26 Xencor, Inc. Heterodimeric proteins
US11053316B2 (en) 2013-01-14 2021-07-06 Xencor, Inc. Optimized antibody variable regions
US10131710B2 (en) 2013-01-14 2018-11-20 Xencor, Inc. Optimized antibody variable regions
US10968276B2 (en) 2013-03-12 2021-04-06 Xencor, Inc. Optimized anti-CD3 variable regions
US9701759B2 (en) 2013-01-14 2017-07-11 Xencor, Inc. Heterodimeric proteins
US9605084B2 (en) 2013-03-15 2017-03-28 Xencor, Inc. Heterodimeric proteins
WO2014113510A1 (en) 2013-01-15 2014-07-24 Xencor, Inc. Rapid clearance of antigen complexes using novel antibodies
RU2528414C1 (en) 2013-01-25 2014-09-20 Закрытое Акционерное Общество "Фарм-Синтез" Cyclic octapeptide, radiopharmaceutical agent based thereon and method of using radiopharmaceutical agent to produce medicinal (pharmaceutical) agents for treating neoplasms expressing somatostatin receptors
NZ711373A (en) 2013-03-13 2020-07-31 Bioasis Technologies Inc Fragments of p97 and uses thereof
US10106624B2 (en) 2013-03-15 2018-10-23 Xencor, Inc. Heterodimeric proteins
US10993420B2 (en) 2013-03-15 2021-05-04 Erasmus University Medical Center Production of heavy chain only antibodies in transgenic mammals
CA3093606A1 (en) 2013-03-15 2014-09-18 Xencor, Inc. Heterodimeric proteins for induction of t cells
CN105324396A (en) 2013-03-15 2016-02-10 艾伯维公司 Dual specific binding proteins directed against il-1 beta and il-17
US10519242B2 (en) 2013-03-15 2019-12-31 Xencor, Inc. Targeting regulatory T cells with heterodimeric proteins
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
RU2652880C2 (en) 2013-04-07 2018-05-03 Дженрикс (Шанхай) Байофармасертикал Ко., Лтд. Epidermal growth factor receptor antibody
US9764039B2 (en) 2013-07-10 2017-09-19 Sutro Biopharma, Inc. Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
AU2014312190A1 (en) 2013-08-28 2016-02-18 Bioasis Technologies Inc. CNS-targeted conjugates of antibodies
SG11201601770YA (en) 2013-09-12 2016-04-28 Halozyme Inc Modified anti-epidermal growth factor receptor antibodies and methods of use thereof
WO2015048008A2 (en) 2013-09-24 2015-04-02 Medimmune, Llc Binding molecules specific for her3 and uses thereof
WO2015054658A1 (en) 2013-10-11 2015-04-16 Sutro Biopharma, Inc. Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
EP3086814B1 (en) 2013-12-23 2020-06-24 Bayer Pharma Aktiengesellschaft Drug conjugates (adcs) with kinesin spindel protein (ksp)
WO2015117121A1 (en) 2014-02-03 2015-08-06 Bioasis Technologies, Inc. P97 fusion proteins
WO2015126729A1 (en) 2014-02-19 2015-08-27 Bioasis Technologies, Inc. P97-ids fusion proteins
SG10202008629XA (en) 2014-03-28 2020-10-29 Xencor Inc Bispecific antibodies that bind to cd38 and cd3
US10745490B2 (en) 2014-04-11 2020-08-18 Celldex Therapeutics, Inc. Anti-ErbB antibodies and methods of use thereof
EP3137610B1 (en) 2014-05-01 2019-03-06 Bioasis Technologies, Inc. P97-polynucleotide conjugates
EP3140392B1 (en) 2014-05-06 2023-07-26 F. Hoffmann-La Roche AG Production of heteromultimeric proteins using mammalian cells
US20170216403A1 (en) 2014-08-12 2017-08-03 Massachusetts Institute Of Technology Synergistic tumor treatment with il-2, a therapeutic antibody, and an immune checkpoint blocker
RU2721271C2 (en) 2014-10-23 2020-05-18 Иннейт Фарма Cancer treatment using anti-nkg2a agents
LT3223845T (en) 2014-11-26 2021-08-25 Xencor, Inc. Heterodimeric antibodies that bind cd3 and cd20
EA037065B1 (en) 2014-11-26 2021-02-01 Ксенкор, Инк. Heterodimeric antibodies that bind cd3 and cd38
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
WO2016094881A2 (en) 2014-12-11 2016-06-16 Abbvie Inc. Lrp-8 binding proteins
WO2016097300A1 (en) 2014-12-19 2016-06-23 Genmab A/S Rodent bispecific heterodimeric proteins
EP3237449A2 (en) 2014-12-22 2017-11-01 Xencor, Inc. Trispecific antibodies
US10227411B2 (en) 2015-03-05 2019-03-12 Xencor, Inc. Modulation of T cells with bispecific antibodies and FC fusions
WO2016171365A1 (en) * 2015-04-23 2016-10-27 신일제약주식회사 Fab fragment specifically binding to egfr
TW201710286A (en) 2015-06-15 2017-03-16 艾伯維有限公司 Binding proteins against VEGF, PDGF, and/or their receptors
MX2017017172A (en) 2015-06-22 2018-02-23 Bayer Pharma AG Antibody drug conjugates (adcs) and antibody prodrug conjugates (apdcs) with enzymatically cleavable groups.
JOP20200312A1 (en) 2015-06-26 2017-06-16 Novartis Ag Factor xi antibodies and methods of use
EP3319996B1 (en) 2015-07-09 2024-01-03 Genmab A/S Bispecific and multispecific antibodies and method for isolation of such
CN108135968A (en) 2015-08-28 2018-06-08 阿穆尼克斯运营公司 Chimeric polyeptides assembly and its preparation and application
WO2017053469A2 (en) 2015-09-21 2017-03-30 Aptevo Research And Development Llc Cd3 binding polypeptides
WO2017060322A2 (en) 2015-10-10 2017-04-13 Bayer Pharma Aktiengesellschaft Ptefb-inhibitor-adc
PL3377103T3 (en) * 2015-11-19 2021-10-04 Revitope Limited Functional antibody fragment complementation for a two-components system for redirected killing of unwanted cells
US11623957B2 (en) 2015-12-07 2023-04-11 Xencor, Inc. Heterodimeric antibodies that bind CD3 and PSMA
WO2017161206A1 (en) 2016-03-16 2017-09-21 Halozyme, Inc. Conjugates containing conditionally active antibodies or antigen-binding fragments thereof, and methods of use
KR20180123047A (en) 2016-03-24 2018-11-14 바이엘 파마 악티엔게젤샤프트 Prodrugs of cytotoxic activators with enzymatically cleavable groups
WO2017201488A1 (en) 2016-05-20 2017-11-23 Harpoon Therapeutics, Inc. Single domain serum albumin binding protein
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
TW201802121A (en) 2016-05-25 2018-01-16 諾華公司 Reversal binding agents for anti-factor XI/XIa antibodies and uses thereof
US10787518B2 (en) 2016-06-14 2020-09-29 Xencor, Inc. Bispecific checkpoint inhibitor antibodies
US11001636B2 (en) 2016-06-15 2021-05-11 Bayer Pharma Aktiengesellschaft Specific antibody-drug-conjugates (ADCs) with KSP inhibitors and anti-CD123-antibodies
US11098107B2 (en) 2016-06-15 2021-08-24 Sutro Biopharma, Inc. Antibodies with engineered CH2 domains, compositions thereof and methods of using the same
CA3029328A1 (en) 2016-06-28 2018-01-04 Xencor, Inc. Heterodimeric antibodies that bind somatostatin receptor 2
US10793632B2 (en) 2016-08-30 2020-10-06 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
MX2019004327A (en) 2016-10-14 2019-10-14 Xencor Inc Bispecific heterodimeric fusion proteins containing il-15/il-15ralpha fc-fusion proteins and pd-1 antibody fragments.
EP3558387B1 (en) 2016-12-21 2021-10-20 Bayer Pharma Aktiengesellschaft Specific antibody drug conjugates (adcs) having ksp inhibitors
WO2018114798A1 (en) 2016-12-21 2018-06-28 Bayer Aktiengesellschaft Prodrugs of cytotoxic active agents having enzymatically cleavable groups
EP3558388A1 (en) 2016-12-21 2019-10-30 Bayer Pharma Aktiengesellschaft Antibody drug conjugates (adcs) having enzymatically cleavable groups
IL308980A (en) 2016-12-23 2024-01-01 Novartis Ag Factor xi antibodies and methods of use
JP2020506208A (en) 2017-02-10 2020-02-27 ゲンマブ ビー．ブイ． Polypeptide variants and their uses
WO2018160754A2 (en) 2017-02-28 2018-09-07 Harpoon Therapeutics, Inc. Inducible monovalent antigen binding protein
KR102376863B1 (en) 2017-05-12 2022-03-21 하푼 테라퓨틱스, 인크. mesothelin binding protein
MA49517A (en) 2017-06-30 2020-05-06 Xencor Inc TARGETED HETERODIMERIC FC FUSION PROTEINS CONTAINING IL-15 / IL-15RA AND AREAS OF ANTIGEN BINDING
WO2019094637A1 (en) 2017-11-08 2019-05-16 Xencor, Inc. Bispecific and monospecific antibodies using novel anti-pd-1 sequences
US10981992B2 (en) 2017-11-08 2021-04-20 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
SG11202005732XA (en) 2017-12-19 2020-07-29 Xencor Inc Engineered il-2 fc fusion proteins
WO2019195623A2 (en) 2018-04-04 2019-10-10 Xencor, Inc. Heterodimeric antibodies that bind fibroblast activation protein
WO2019195959A1 (en) 2018-04-08 2019-10-17 Cothera Biosciences, Inc. Combination therapy for cancers with braf mutation
WO2019204665A1 (en) 2018-04-18 2019-10-24 Xencor, Inc. Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof
EP3781598A1 (en) 2018-04-18 2021-02-24 Xencor, Inc. Tim-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and tim-3 antigen binding domains
EP3810649A1 (en) 2018-06-22 2021-04-28 Genmab A/S Method for producing a controlled mixture of two or more different antibodies
SG11202103022WA (en) 2018-09-25 2021-04-29 Harpoon Therapeutics Inc Dll3 binding proteins and methods of use
KR20210068478A (en) 2018-09-28 2021-06-09 메사추세츠 인스티튜트 오브 테크놀로지 Collagen-localized immunomodulatory molecules and methods thereof
WO2020072821A2 (en) 2018-10-03 2020-04-09 Xencor, Inc. Il-12 heterodimeric fc-fusion proteins
CN113330033A (en) 2018-12-26 2021-08-31 先天制药公司 Leukocyte immunoglobulin-like receptor 2 neutralizing antibodies
WO2020154032A1 (en) 2019-01-23 2020-07-30 Massachusetts Institute Of Technology Combination immunotherapy dosing regimen for immune checkpoint blockade
KR20210134725A (en) 2019-03-01 2021-11-10 젠코어 인코포레이티드 Heterodimeric Antibodies that Bind to ENPP3 and CD3
WO2020252043A1 (en) 2019-06-10 2020-12-17 Sutro Biopharma, Inc. 5H-PYRROLO[3,2-d]PYRIMIDINE-2,4-DIAMINO COMPOUNDS AND ANTIBODY CONJUGATES THEREOF
US11246906B2 (en) 2019-06-11 2022-02-15 Alkermes Pharma Ireland Limited Compositions and methods for subcutaneous administration of cancer immunotherapy
JP2022536800A (en) 2019-06-17 2022-08-18 ストロ バイオファーマ インコーポレーテッド 1-(4-(aminomethyl)benzyl)-2-butyl-2H-pyrazolo[3,4-C]quinolin-4-amine derivatives and related compounds as TOLL-like receptor (TLR) 7/8 agonists, and antibody drug conjugates thereof for use in cancer therapy and diagnosis
JP2022538974A (en) 2019-06-26 2022-09-07 マサチューセッツ インスチテュート オブ テクノロジー Immunomodulatory fusion protein-metal hydroxide complexes and methods thereof
KR20220053587A (en) * 2019-08-09 2022-04-29 에이투 바이오쎄라퓨틱스, 인크. Cell surface receptors responsive to loss of heterozygosity
US20230023070A1 (en) 2019-12-02 2023-01-26 Celegene Corporation Therapy for the Treatment of Cancer
WO2021178597A1 (en) 2020-03-03 2021-09-10 Sutro Biopharma, Inc. Antibodies comprising site-specific glutamine tags, methods of their preparation and methods of their use
WO2021231976A1 (en) 2020-05-14 2021-11-18 Xencor, Inc. Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3
CA3128035A1 (en) 2020-08-13 2022-02-13 Bioasis Technologies, Inc. Combination therapies for delivery across the blood brain barrier
AU2021329375A1 (en) 2020-08-20 2023-04-20 A2 Biotherapeutics, Inc. Compositions and methods for treating ceacam positive cancers
CA3188862A1 (en) 2020-08-20 2022-02-24 Carl Alexander Kamb Compositions and methods for treating mesothelin positive cancers
WO2022103983A2 (en) 2020-11-11 2022-05-19 Sutro Biopharma, Inc. Fluorenylmethyloxycarbonyl and fluorenylmethylaminocarbonyl compounds, protein conjugates thereof, and methods for their use
KR20230156079A (en) 2021-03-09 2023-11-13 젠코어 인코포레이티드 Heterodimeric antibody binding to CD3 and CLDN6
WO2022192586A1 (en) 2021-03-10 2022-09-15 Xencor, Inc. Heterodimeric antibodies that bind cd3 and gpc3
KR102415292B1 (en) 2022-04-04 2022-07-01 (주)청수 High-concentration complex odor treatment system
US20240091365A1 (en) 2022-06-27 2024-03-21 Sutro Biopharma, Inc. Beta-glucuronide linker-payloads, protein conjugates thereof, and methods thereof
WO2024015229A1 (en) 2022-07-15 2024-01-18 Sutro Biopharma, Inc. Protease/enzyme cleavable linker-payloads and protein conjugates

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4943533A (en) * 1984-03-01 1990-07-24 The Regents Of The University Of California Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
US5643759A (en) * 1993-10-30 1997-07-01 Biotest Pharma Gmbh Method for preparing bispecific monoclonal antibodies
US5844093A (en) * 1994-03-17 1998-12-01 Merck Patent Gesellschaft Mit Beschrankter Haftung Anti-EGFR single-chain Fvs and anti-EGFR antibodies
US5874299A (en) * 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4954617A (en) * 1986-07-07 1990-09-04 Trustees Of Dartmouth College Monoclonal antibodies to FC receptors for immunoglobulin G on human mononuclear phagocytes
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
US5470571A (en) 1988-01-27 1995-11-28 The Wistar Institute Method of treating human EGF receptor-expressing gliomas using radiolabeled EGF receptor-specific MAB 425
AU4128089A (en) 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
US5705157A (en) 1989-07-27 1998-01-06 The Trustees Of The University Of Pennsylvania Methods of treating cancerous cells with anti-receptor antibodies
US5459061A (en) 1990-01-26 1995-10-17 W. Alton Jones Cell Science Center, Inc. Hybridomas producing monoclonal antibodies which specifically bind to continuous epitope on the human EGF receptor and compete with EGF for binding to the EGF receptor
US5218090A (en) 1990-06-12 1993-06-08 Warner-Lambert Company EGF receptor truncates
WO1993000917A1 (en) 1991-07-05 1993-01-21 Seragen, Inc. Epidermal growth factor receptor targeted molecules for treatment of inflammatory arthritis
EP0586002B1 (en) 1992-08-18 2000-01-19 CENTRO de IMMUNOLOGIA MOLECULAR Monoclonal antibodies recognizing the epidermal growth factor receptor, cells and methods for their production and compositions containing them
IT1271461B (en) 1993-12-01 1997-05-28 Menarini Ricerche Sud Spa ANTI-CD3 / ANTI-EGFR MONOCLONAL ANTI-BODY ANTIBODY, PROCESS FOR PRODUCTION AND ITS USE.
GB9401182D0 (en) 1994-01-21 1994-03-16 Inst Of Cancer The Research Antibodies to EGF receptor and their antitumour effect
PT706799E (en) 1994-09-16 2002-05-31 Merck Patent Gmbh IMUNOCONJUGADOS II
US6538114B1 (en) * 1996-04-19 2003-03-25 Karolina Innovations Ab Human monoclonal antibodies specific for hepatitis C virus (HCV) E2 antigen
US5708156A (en) 1996-05-31 1998-01-13 Ilekis; John V. Epidermal growth factor receptor-like gene product and its uses
US6235883B1 (en) * 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
ATE322909T1 (en) 1998-12-21 2006-04-15 Ludwig Inst Cancer Res ANTIBODIES TO SHORTENED VEGF-D AND THEIR USES
MXPA02000962A (en) * 1999-07-29 2002-07-02 Medarex Inc Human monoclonal antibodies to her2 neu.
US6794132B2 (en) * 1999-10-02 2004-09-21 Biosite, Inc. Human antibodies
US6680209B1 (en) * 1999-12-06 2004-01-20 Biosite, Incorporated Human antibodies as diagnostic reagents
BR0110610A (en) 2000-04-11 2003-04-29 Genentech Inc Isolated antibodies, immunoconjugates, polypeptide chains, isolated nucleic acid, vector, host cell, antibody or polypeptide chain production process, method of treating mammalian dysfunction, method of inducing apoptosis of a cancer cell, method of killing a cell b, method for killing a cell expressing an erbb receptor and uses of isolated antibodies
KR100480985B1 (en) 2000-05-19 2005-04-07 이수화학 주식회사 Humanized antibodies to the epidermal growth factor receptor
EP1170011A1 (en) 2000-07-06 2002-01-09 Boehringer Ingelheim International GmbH Novel use of inhibitors of the epidermal growth factor receptor
AU9500201A (en) 2000-08-09 2002-02-18 Imclone Systems Inc Treatment of hyperproliferative diseases with epidermal growth factor receptor antagonists

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4943533A (en) * 1984-03-01 1990-07-24 The Regents Of The University Of California Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
US5874299A (en) * 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5643759A (en) * 1993-10-30 1997-07-01 Biotest Pharma Gmbh Method for preparing bispecific monoclonal antibodies
US5844093A (en) * 1994-03-17 1998-12-01 Merck Patent Gesellschaft Mit Beschrankter Haftung Anti-EGFR single-chain Fvs and anti-EGFR antibodies

Also Published As

Publication number Publication date
BR0210405A (en) 2005-04-19
BRPI0210405B8 (en) 2021-05-25
CZ200438A3 (en) 2004-06-16
EP1417232B1 (en) 2014-12-03
AU2002345673B2 (en) 2007-04-26
WO2002100348A8 (en) 2003-04-10
KR20090125840A (en) 2009-12-07
CN1966525A (en) 2007-05-23
US20030091561A1 (en) 2003-05-15
KR20040016883A (en) 2004-02-25
NZ530212A (en) 2006-09-29
KR100945108B1 (en) 2010-03-02
JP4298498B2 (en) 2009-07-22
WO2002100348A2 (en) 2002-12-19
RU2004100834A (en) 2005-03-27
RU2335507C2 (en) 2008-10-10
JP2005501529A (en) 2005-01-20
CA2450285C (en) 2016-08-02
EP1417232A4 (en) 2005-04-27
BRPI0210405B1 (en) 2018-11-27
HK1064685A1 (en) 2005-02-04
US7247301B2 (en) 2007-07-24
EP1417232A2 (en) 2004-05-12
MXPA03011365A (en) 2005-03-07
CN100497389C (en) 2009-06-10
CN1610695A (en) 2005-04-27
JP2009148282A (en) 2009-07-09
IL159225A (en) 2009-09-01
HUP0600225A2 (en) 2006-06-28
CA2450285A1 (en) 2002-12-19
HUP0600225A3 (en) 2010-01-28
IL159225A0 (en) 2004-06-01

Similar Documents

Publication Publication Date Title
WO2002100348A8 (en) Human monoclonal antibodies to epidermal growth factor receptor (egfr)
WO2004056847A3 (en) Human monoclonal antibodies to epidermal growth factor receptor (egfr)
LTPA2021514I1 (en)
WO2003064606A3 (en) Human monoclonal antibodies to prostate specific membrane antigen (psma)
WO2003017935A3 (en) Human antibodies specific for interleukin 15 (il-15)
WO2004076620A3 (en) Human antibodies specific for interleukin 15 (il-15)
WO2001009187A3 (en) Human monoclonal antibodies to her2/neu
WO2004045512A3 (en) Human monoclonal antibodies against cd25
CA2380783A1 (en) Human monoclonal antibodies to prostate specific membrane antigen
WO2004058797A3 (en) Human monoclonal antibodies against interleukin 8 (il-8)
WO2003040169A3 (en) Human monoclonal antibodies to dendritic cells
WO2004043989A3 (en) Human monoclonal antibodies to heparanase
WO2003059282A3 (en) Human monoclonal antibodies against cd30
WO2001085798A3 (en) Human monoclonal antibodies to dendritic cells
RS20050724A (en) Human antibodies specific for interleukin 15(il-15)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: UNDER (30) REPLACE "69/298172" BY "60/298172"

WWE Wipo information: entry into national phase

Ref document number: 159225

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: PA/a/2003/011365

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2450285

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003503174

Country of ref document: JP

Ref document number: 1020037016294

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2002345673

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 530212

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: PV2004-38

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: 70/CHENP/2004

Country of ref document: IN

Ref document number: 2002744320

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2002815939X

Country of ref document: CN

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2002744320

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: PV2004-38

Country of ref document: CZ

WWG Wipo information: grant in national office

Ref document number: 2002345673

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1020097022335

Country of ref document: KR